Hybrid Cell Membrane‐based Nanoplatforms for Enhanced Immunotherapy Against Cancer and Infectious Diseases

Abstract Immunotherapy based on nanoplatforms is a promising approach to treat cancer and infectious diseases, and it has achieved considerable progress in clinical practices. Cell membrane‐based nanoplatforms endow nanoparticles with versatile characteristics, such as half‐life extension, targeting ability, and immune‐system regulation. However, monotypic cell membrane usually fails to provoke strong immune response for immunotherapy while maintaining good biosafety. The integration of different cell‐membrane types provides a promising approach to construct multifunctional nanoplatforms for improved immunotherapeutic efficacy by enhancing immunogenicity or targeting function, evading immune clearance, or combining with other therapeutic modalities. In this review, we first discuss the design principles, preparation strategies and applications of hybrid cell membrane‐based nanoplatforms for cancer and infection immunotherapy. Furthermore, we discuss the challenges and prospects for the potential clinical translation of hybrid cell membrane‐based nanoplatforms. This article is protected by copyright. All rights reserved